Kestra Medical Technologies Inc
NASDAQ:KMTS
Kestra Medical Technologies Inc
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington. The company went IPO on 2025-03-06. The firm is focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies. The company has developed and commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform include the ASSURE WCD, a next generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. In addition to the ASSURE WCD, its Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services.
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington. The company went IPO on 2025-03-06. The firm is focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies. The company has developed and commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform include the ASSURE WCD, a next generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. In addition to the ASSURE WCD, its Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services.
Revenue Growth: Kestra reported Q2 revenue of $22.6 million, up 53% year-over-year, driven by a 54% increase in prescriptions.
Gross Margin Milestone: Gross margin topped 50% for the first time, reaching 51.6%, and management expects further expansion toward 70%.
Guidance Raised: FY26 revenue guidance was increased to $91 million (up 52% YoY), compared to previous guidance of $88 million.
Market Expansion: The wearable cardioverter defibrillator (WCD) market is now growing at low double digits, with Kestra seeing both share gains and overall market growth.
Clinical Evidence: Results from the 21,000-patient ACE-PAS study reinforced the effectiveness and safety of Kestra’s ASSURE system, with high wear time and low false alarms.
Sales Force Expansion: Active sales territories grew to about 100 (up from 80 last year), with further hiring planned.
Improved Conversion Rate: Conversion rate improved to 48.8% in Q2 from 48.2% last year, aided by higher in-network payer mix and enhanced revenue cycle management.
